Table 3.
Antibiotics prescribed during the hospitalization and at discharge
| Non-purulent cellulitis n=320 |
Wound infection or purulent cellulitis n=44 |
Cutaneous abscess n=169 |
Total n =533 |
|
|---|---|---|---|---|
| Inpatient antibiotic therapy | ||||
| Antibiotic regimen ordered by admitting provider | ||||
| Single antibiotic | 202 (63) | 29 (66) | 111 (66) | 342 (64) |
| Combination antibiotic regimen | 117 (37) | 15 (34) | 58 (34) | 190 (36) |
| Individual antibiotics prescribed during the inpatient stay a, b | ||||
| Parenteral antibiotics | ||||
| Vancomycin | 226 (71) | 27 (61) | 138 (82) | 391 (73) |
| Clindamycin | 88 (28) | 21 (48) | 42 (25) | 151 (28) |
| β-lactam/β-lactamase inhibitor | 73 (23) | 11 (25) | 51 (30) | 135 (25) |
| 2nd generation or higher cephalosporin | 53 (17) | 5 (11) | 16 (9) | 74 (14) |
| Cefazolin | 46 (14) | 8 (18) | 17 (10) | 71 (13) |
| Carbapenem | 29 (9) | 2 (5) | 10 (6) | 41 (8) |
| Fluoroquinolone | 25 (8) | 3 (7) | 9 (5) | 37 (7) |
| Daptomycin | 24 (8) | 1 (2) | 7 (4) | 32 (6) |
| Linezolid | 6 (2) | 1 (2) | 1 (1) | 8 (2) |
| Other β-lactam | 13 (4) | 3 (7) | 3 (2) | 19 (4) |
| Oral antibiotics | ||||
| Clindamycin | 24 (8) | 6 (14) | 21 (12) | 51 (10) |
| Trimethoprim-sulfamethoxazole | 25 (8) | 4 (9) | 21 (12) | 50 (9) |
| Doxycycline | 18 (6) | 2 (5) | 10 (6) | 30 (6) |
| Cephalexin | 23 (7) | 0 | 5 (3) | 28 (5) |
| Fluoroquinolone | 17 (5) | 2 (5) | 8 (5) | 27 (5) |
| Amoxicillin-clavulanate | 9 (3) | 1 (2) | 10 (6) | 20 (4) |
| Other β-lactam | 2 (1) | 0 | 4 (2) | 6 (1) |
| Antibiotic with broad gram-negative activity | 136 (43) | 15 (34) | 58 (34) | 209 (39) |
| Antibiotic therapy prescribed at hospital discharge b | 309 (97) | 44 (100) | 166 (98) | 519 (97) |
| Single antibiotic | 251 (78) | 35 (80) | 140 (83) | 426 (80) |
| Combination antibiotic regimen | 58 (18) | 9 (20) | 25 (15) | 92 (17) |
| Parenteral antibiotics | 32 (10) | 6 (14) | 9 (5) | 47 (9) |
| Vancomycin | 12 (4) | 4 (9) | 4 (2) | 20 (4) |
| Daptomycin | 12 (4) | 1 (2) | 2 (1) | 15 (3) |
| Other parenteral antibiotic c | 10 (3) | 1 (2) | 4 (2) | 15 (3) |
| Oral antibiotics | 276 (86) | 40 (91) | 159 (94) | 475 (89) |
| Clindamycin | 75 (23) | 19 (43) | 48 (28) | 142 (27) |
| Trimethoprim-sulfamethoxazole | 63 (20) | 12 (27) | 43 (25) | 118 (22) |
| Doxycycline | 40 (13) | 2 (5) | 26 (15) | 68 (13) |
| Cephalexin | 46 (14) | 3 (7) | 17 (10) | 66 (12) |
| Amoxicillin-clavulanate | 39 (12) | 4 (9) | 21 (12) | 64 (12) |
| Fluoroquinolone | 27 (8) | 2 (5) | 12 (7) | 41 (8) |
| Linezolid | 23 (7) | 1 (2) | 3 (2) | 27 (5) |
| Other β-lactam | 15 (5) | 3 (7) | 8 (5) | 26 (5) |
| Other d | 1 (0.3) | 1 (2) | 2 (1) | 4 (1) |
| Antibiotic with broad gram-negative activity | 78 (24) | 8 (18) | 36 (21) | 122 (23) |
| Treatment duration e | ||||
| Total duration of therapy, median days (IQR) | 12 (10–15) | 12 (11–14) | 12 (10–15) | 12 (10–15) |
| Duration of inpatient therapy, median days (IQR) | 4 (3–5) | 3 (3–4) | 4 (3–5) | 4 (3–5) |
| Duration of therapy after discharge, median days (IQR) | 8 (7–10) | 10 (7–10) | 9 (7–10) | 8 (7–10) |
Data presented as n (%) unless otherwise noted. IQR, interquartile range.
a
Includes antibiotics initiated by the emergency department, urgent care, or clinic.
b
Patients could receive more than one antibiotic.
c
Includes carbapenem (6), ceftriaxone (4), ceftaroline (1), nafcillin (1), linezolid (1), rifampin (1), trimethoprim-sulfamethoxazole (1), levofloxacin (1).
d
Includes metronidazole (3), erythromycin (1)
e
Analyses limited to 492 cases with a known duration of therapy.